Clearbridge    Last:0.002   -

SARS RELATED PLAYS..

ya lor should push up soon.

Sgvale      ( Date: 05-Feb-2020 21:39) Posted: Clearbridge owns the largest chain of clinical laboratories and renal dialysis centres co-located in some of the best hospitals in Indonesia. In Singapore, the group has also acquired a medical-cum-aesthetic clinic and a chain of dental clinics. Clearbridge 24.8%-owned associate Biolidics has been making waves in China. Still below 0.20?

 

Clearbridge owns the largest chain of clinical laboratories and renal dialysis centres co-located in some of the best hospitals in Indonesia.
In Singapore, the group has also acquired a medical-cum-aesthetic clinic and a chain of dental clinics.
Clearbridge 24.8%-owned associate Biolidics has been making waves in China.

Still below 0.20?

 

This loss-making healthcare group could be a ' potential unicorn' and treble in value, says Tayrona

SINGAPORE (Feb 5): Emerging areas of precision medicine could transform loss-making healthcare group Clearbridge Health into a &ldquo potential unicorn in the making&rdquo , according to Tayrona Financial, the independent equity research house formerly known as NRA Capital.

  &ldquo We see high growth potential for the company as doctors increasingly customise treatments to patients&rsquo genetic composition,&rdquo says analyst Liu Jinshu in a Jan 31 report. &ldquo With its network across Asia, Clearbridge is positioning itself to tap on this trend over the next five to ten years.&rdquo

  According to Liu, such growing markets in precision medicine include direct-to-consumer DNA tests, drug sensitivity testing and cancer treatment.

  Liu notes that Clearbridge has been growing its portfolio of healthcare facilities through acquisitions over the past two years.

  Clearbridge now owns the largest chain of clinical laboratories and renal dialysis centres co-located in some of the best hospitals in Indonesia.

 

  In Singapore, the group has also acquired a medical-cum-aesthetic clinic and a chain of dental clinics.

  Meanwhile, Clearbridge&rsquo s 24.8%-owned associate Biolidics has been making waves in China. This includes working with partners to develop clinical and laboratory tests using its patented technology to separate tumour cells from blood.

  &ldquo Liquid biopsies can be used to detect cancer early and monitor disease and has been touted as a game changer in cancer treatment. In the US, similar companies have captured the attention of pharma giants and have been the subject of several acquisitions over the last two years,&rdquo Liu says.

  For now, however, Clearbridge has been unable to climb out from the red.

  For 9MFY2019 ended September 2019, the group posted a net loss of $8.2 million, down from a net loss of $16.2 million in the corresponding period a year ago.

  9MFY2019 revenue more than trebled to $13.2 million, from $3.9 million a year ago, on the back of strong contributions from its recent healthcare acquisitions.

  &ldquo With a stream of profitable acquisitions, we expect Clearbridge to turn EBITDA positive in 2020 and report its maiden profit in 2021,&rdquo Liu says. He notes that the company&rsquo s management has a track record of running and monetising medical technology businesses.

  Nonetheless, Liu is not too worried about Clearbidge&rsquo s ability to turn a profit. After all, he argues, other loss-making precision medicine companies have managed to successfully attract attention for their technologies and market presence.

 

  For example, Liu points out that Foundation Medicine was acquired by Roche for US$2.4 billion ($3.3 billion), and that Guardant Health has a market capitalisation of US$7.42 billion.

  &ldquo We believe that Clearbridge deserves an aggressive valuation for its high future growth potential. Hence, we value Clearbridge at US$201.3 million,&rdquo Liu says.

  This translates to a fair value estimate of 41 cents &ndash representing a potential upside of 195% from Clearbridge&rsquo s closing price of 13.9 cents on Wednesday.

  The research house has an &ldquo overweight&rdquo rating on the counter.

http://www.theedgesingapore.com/capital/brokers-calls/loss-making-healthcare-group-could-be-potential-unicorn-and-treble-value-says

 

This still safe to play without virus. Still have dental. Medical clinic. Lab.

 

Think contra sell off today. Buy up 139 last min new player

Battle123      ( Date: 05-Feb-2020 19:15) Posted: Shld have a bounce soon

 

Shld have a bounce soon

 

Still not bad close 139

guards80      ( Date: 05-Feb-2020 16:47) Posted: Sian.  Sgvale      ( Date: 05-Feb-2020 16:46) Posted: Why Dow everyday Huat? Even China market also huat. Singapore looks like the epicentr

 

Sian. 

Sgvale      ( Date: 05-Feb-2020 16:46) Posted: Why Dow everyday Huat? Even China market also huat. Singapore looks like the epicentre guards80      ( Date: 05-Feb-2020 16:38) Posted: Dow kisiao +15

 

Why Dow everyday Huat? Even China market also huat. Singapore looks like the epicentre

guards80      ( Date: 05-Feb-2020 16:38) Posted: Dow kisiao +150 guards80      ( Date: 05-Feb-2020 16:36) Posted: Wow dow rocket up +90

 

Dow kisiao +150

guards80      ( Date: 05-Feb-2020 16:36) Posted: Wow dow rocket up +90

 

Wow dow rocket up +90

 

Huat ah. Since medtec rebound this going follow up

Sgvale      ( Date: 05-Feb-2020 16:22) Posted: Co prospect looks good . I already in another 50 lots. Will disregard the short term weakness

 

Co prospect looks good . I already in another 50 lots. Will disregard the short term weakness

 

I think today may not have show, hopefully start tmr

Damn those crook brokerage houses


 

guards80      ( Date: 05-Feb-2020 15:54) Posted: Fewday no power up. 4.30pm power up? Or tmr?

 

Fewday no power up. 4.30pm power up? Or tmr?

 

Must scold scold the syndicates , crook broker houses.

Medical stocks

 

guards80      ( Date: 05-Feb-2020 14:30) Posted: lowest so fasr is 132. but i think wont 132 liaoz. saw 137 few time past trading good support. Battle123      ( Date: 05-Feb-2020 14:26) Posted: Some people say got syndicates trying to lower the price kelong.... But i think long term will rise

 

Clearbridge Health in private placement to raise $11.3 mil to speed up Asia growth plans

SINGAPORE (July 29): Clearbridge Health is raising $11.34 million from a share placement exercise to accelerate its growth plans in Asia&rsquo s healthcare market.

  Under the terms of the share placement agreement, Clearbridge, will issue some 80.5 million new ordinary shares at 14.1 cents each.

  This is a discount of 9.96% to its volume weighted average price of 15.66 cents each, for all trade trades done on Catalist on Friday, the full market day before which the placement agreements were signed.

  Subscribers of the share placement included Macondray Company and Coop International.

  Macondray Company is part of Macondray Philippines Co Inc, the private, Filipino-owned investment holding group.

 

  Coop International, a wholly-owned subsidiary of SGX-listed Bonvests Holdings which is an existing shareholder of Clearbridge and will become a substantial shareholder of Clearbridge after the share placement.

  Currently, Clearbridge has three strategic business units or SBUs.

  In the first unit of Healthcare services, Clearbridge has a network of medical centres and clinics in the Philippines, Hong Kong, Malaysia and Singapore

  Under Medical healthcare systems, the group operates pathology laboratories in Singapore and Philippines and manages a total of 56 hospital joint operation contracts (JOs) in Indonesia, Medical healthcare systems through the provision of healthcare-related services.

  Lastly, under Strategic equity investment, Clearbridge has investments in three different medical technology companies. Notably, it is the largest shareholder of SGX-listed Biolidics.

  As at 10.28am, shares in Clearbridge are down 0.5 cent at 15 cents.

 

http://www.clearbridgehealth.com/

 

Sgvale      ( Date: 05-Feb-2020 14:33) Posted: May enter again when buy volume increase

 

May enter again when buy volume increase